APAC ECMO Market Outlook to 2028

APAC ECMO Market Overview

The APAC ECMO market, valued at USD 70 million based on a five-year historical analysis, has experienced steady growth driven by the rising incidence of respiratory and cardiac disorders, increasing healthcare expenditure, and the expanding availability of advanced ECMO devices across the region. With the increasing application of ECMO for critical care and respiratory support, the market is witnessing robust demand, especially in countries with advanced healthcare infrastructure.

Countries such as China, Japan, and South Korea dominate the ECMO market in the APAC region due to their well-established healthcare systems, advanced medical technology, and higher healthcare expenditure. Japan, in particular, benefits from a well-developed ECMO infrastructure and strong research capabilities, while China is experiencing rapid growth due to increasing investments in healthcare and government efforts to improve medical device manufacturing. South Korea also contributes significantly with its advanced medical technology and focus on ECMO-based treatments in tertiary care hospitals.

Hybrid ECMO systems, which combine multiple life-support functionalities such as dialysis and ventilation, are gaining traction in APAC. Hospitals in South Korea and Singapore have been at the forefront of adopting these systems. The South Korean Ministry of Health reported a 10% year-over-year increase in the adoption of hybrid ECMO systems in tertiary care centers in 2023. These systems offer enhanced efficiency, reducing the need for multiple machines and improving patient care in intensive care units.

APAC ECMO Market Segmentation

By Component: The APAC ECMO market is segmented by components into pumps, oxygenators, cannulas, controllers, and others. Among these, oxygenators dominate the market share due to their critical role in oxygen exchange during ECMO procedures. Oxygenators are integral in supporting both cardiac and respiratory functions during ECMO, especially for patients with severe lung failure or cardiac issues. The increasing cases of respiratory failure, along with advancements in oxygenator technology, contribute to this segments dominant position.

By Modality: The APAC ECMO market is segmented by modality into Veno-Arterial (VA) ECMO, Veno-Venous (VV) ECMO, and Arterio-Venous (AV) ECMO. Veno-Venous ECMO holds the dominant market share due to its widespread use in treating severe respiratory failure. The demand for VV ECMO has surged significantly, particularly in treating COVID-19-related respiratory distress. Additionally, VV ECMO is favored for its ability to provide long-term respiratory support without the need for invasive surgical interventions.

APAC ECMO Market Competitive Landscape

The APAC ECMO market is dominated by a handful of major players who lead the market through technological innovations, strategic partnerships, and expansion into emerging economies. These players invest heavily in R&D, contributing to advancements in ECMO systems, making them more portable, efficient, and accessible. Notable among them are companies like Medtronic and Getinge AB, which have extensive product portfolios catering to the ECMO market.

Company

Establishment Year

Headquarters

Revenue (USD Bn)

No. of Employees

R&D Spend (USD Mn)

Market Share (2023)

Key Products

Partnerships

Innovation Index

Medtronic Plc

1949

Dublin, Ireland

Getinge AB

1904

Gothenburg, Sweden

Terumo Corporation

1921

Tokyo, Japan

Liva Nova Plc

2015

London, UK

Xenios AG (Fresenius)

2013

Heilbronn, Germany

APAC ECMO Industry Analysis

Market Growth Drivers

Increased Incidence of Respiratory and Cardiac Disorders The rising incidence of respiratory and cardiac disorders is a significant driver for ECMO (Extracorporeal Membrane Oxygenation) adoption across the APAC region. According to the World Health Organization, in 2022, 17.9 million deaths globally were due to cardiovascular diseases, with 80% occurring in low- and middle-income countries, including many APAC nations. The rise in pollution and smoking in densely populated areas such as China and India contributes to a growing number of patients suffering from Chronic Obstructive Pulmonary Disease (COPD) and other respiratory disorders. These statistics point to a growing demand for ECMO treatment as an essential intervention for critical cases of heart and lung failure.

Growing Adoption of ECMO in Neonatal and Pediatric Care: The application of ECMO in neonatal and pediatric care has witnessed notable growth, driven by the rise in infant mortality and premature births across APAC. UNICEF's 2023 report highlights that over 2.4 million neonatal deaths were recorded globally, with a significant portion occurring in South and Southeast Asia. Advances in neonatal care are pushing hospitals to adopt ECMO technology to manage severe cases of respiratory distress syndrome in infants. For instance, in India, where infant mortality remains high at 27 per 1,000 live births in 2022, ECMO is being integrated into healthcare frameworks, showcasing the growing adoption of this life-saving technology.

Technological Advancements in ECMO Systems: Recent technological advancements in ECMO systems, including better oxygenator efficiency and compact, portable designs, have further supported their adoption across APAC. In 2023, Japan and South Korea, recognized for their robust healthcare R&D infrastructure, invested significantly in enhancing ECMO system efficiency, aligning with WHO's recommendations for improved intensive care unit (ICU) technologies. The innovation of miniaturized ECMO machines has enabled their use outside traditional hospital settings, making them a viable option for emergency care and long-distance transportation of critical patients in remote regions.

Market Restraints

Limited Availability of Skilled Professionals: The ECMO market in APAC faces a shortage of skilled professionals capable of operating this advanced technology. According to the WHO, there is a significant healthcare worker deficit in the APAC region, with a shortfall of 1.5 million healthcare professionals reported in 2023. Countries like Indonesia and the Philippines are struggling with a brain drain of medical talent, further straining the healthcare workforce. As ECMO requires specialized training for both initiation and management, the lack of skilled personnel is a critical barrier to its widespread implementation.

Lack of Reimbursement Policies in Developing Markets: In many APAC countries, particularly in developing economies like Laos and Myanmar, the lack of proper reimbursement policies is a critical challenge impeding ECMOs accessibility. Government-backed insurance schemes in these regions often do not cover advanced treatments like ECMO. This results in out-of-pocket expenditures for patients, who may need to pay thousands of dollars per treatment. The World Bank reported in 2023 that over 40% of healthcare costs in low-income APAC countries are borne by individuals, a factor that severely limits the adoption of expensive medical technologies like ECMO.

APAC ECMO Market Future Outlook

Over the next five years, the APAC ECMO market is expected to exhibit significant growth, driven by continuous advancements in ECMO technology, increasing healthcare infrastructure, and growing awareness of ECMO as a life-saving treatment option. The rise in the prevalence of respiratory and cardiac disorders, coupled with the expanding geriatric population in countries like Japan and South Korea, will also contribute to market growth. Additionally, government initiatives to boost healthcare expenditure and improve medical device manufacturing capabilities across the APAC region will foster growth in this sector.

Market Opportunities

Expansion in Emerging Economies: Emerging APAC economies like India, Indonesia, and Vietnam are poised for growth in the ECMO market. In 2023, Indias healthcare sector saw a $6 billion investment from the government and private sector, focusing on expanding advanced medical infrastructure in urban and semi-urban areas. The increased focus on healthcare reform, driven by macroeconomic policies aimed at boosting GDP growth through healthcare investments, presents a significant opportunity for ECMO system manufacturers to penetrate these expanding markets.

Increased Use of ECMO During Post-Surgical Recovery: ECMO is gaining traction as a critical support system during post-surgical recovery, especially for patients undergoing major heart surgeries. In 2023, over 100,000 heart surgeries were performed in APAC, with a growing number of hospitals integrating ECMO into post-operative care to manage complications such as heart failure. Japan and South Korea have led the region in ECMO usage for surgical recovery, with government data reporting a 15% increase in post-operative ECMO usage in tertiary care centers.
Please Note: It will take 5-7 business days to complete the report upon order confirmation